טוען...
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B infection post-liver transplantation
BACKGROUND: Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear. OBJECTIVE: To evaluate the use of tenofovir...
שמור ב:
Main Authors: | , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Pulsus Group Inc
2014
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4071906/ https://ncbi.nlm.nih.gov/pubmed/24212911 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|